Three Subsidiaries of MicroPort® Awarded the Title of 2018 Shanghai Municipality Specialized, Refined, Characteristic and Novel Small and Medium-Size Enterprise

Shanghai, China – The Shanghai Municipal Commission of Economy and Informatization made public the list of 2018 Shanghai Municipality Specialized, Refined, Characteristic and Novel Small and Medium-Size Enterprises on February 12. A total of three subsidiary companies of Shanghai MicroPort Medical (Group) Co., Ltd. (“MicroPort®”), which are Shanghai MicroPort EP MedTech Co., Ltd. (“MicroPort® EP”), Shanghai MicroPort Endovascular MedTech Co., Ltd. (“MicroPort® Endovascular”), and MicroPort NeuroTech (Shanghai) Co., Ltd. (“MicroPort® NeuroTech”), are included in the list, making the first-time mention for MicroPort® NeuroTech as well as the second time for MicroPort® EP and MicroPort® Endovascular.

 

Guiding the small and medium-size enterprises to become Specialized, Refined, Characteristic and Novel is one of the major measures taken by the Chinese Communist Party Central and the State Council to promote the high-quality development for the small and medium-size enterprises. Since Shanghai launched the Project on the Cultivation of Specialized, Refined, Characteristic and Novel Small and Medium-Size Enterprises in 2011, the Shanghai Municipal Commission of Economy and Informatization have been adhering to the Specialized, Refined, Characteristic and Novel approach to discover and cultivate a batch of high-growth enterprises that concentrate on the core business, possess independent intellectual property, own unique processes and techniques, and have competitive advantages.

 

The universal requirements to qualify as a Specialized, Refined, Characteristic and Novel Small and Medium-Size Enterprise are: the annual revenue in the previous year should amount to no less than 10 million yuan, and the year-over-year revenue growth in the most recent year should not be lower than 15% in principle; or the average year-over-year revenue growth in the past two consecutive years should not be lower than 10% in principle. In addition, there are special requirements: Specialized means that the enterprises should concentrate on their core business and rank among the top 10 in their respective market segments; Refined means that they should have refined production, management or service; Characteristic means that they should have the characteristics of uniqueness and exclusive production; and Novel means that they should have innovation in techniques and management and form the novel competitive advantages.


MicroPort® EP was founded in 2010 and is dedicated to the R&D, production, marketing of various kinds of medical devices and equipment that are related to the interventional diagnosis and treatment in cardiac electrophysiology, including ablation catheters, diagnosis catheters, and 3D EP navigation systems. MicroPort® Endovascular was established in 2012 and produces mainly aortic stent-graft systems, stent-graft systems in surgical operation, and big balloons and peripheral vascular stents. MicroPort® NeuroTech was founded in 2012 and is committed to the R&D, manufacturing, marketing, and technical support of the medical devices that treat the central nervous system diseases. The products of the three companies are widely used at Chinese top-tier hospitals and exported to many foreign countries and regions. Previously, they had won the titles of Shanghai Municipality Science and Technology Young Giant Enterprise, Shanghai Municipality High and New-Tech Enterprise, and Shanghai Municipality Patent Work Pilot Enterprise for several times.

 

MicroPort® and its subsidiary companies are always focused on independent innovation and constantly make above industry average investment in research and development. The Shanghai Municipal Government awarded the title of 2018 Shanghai Municipality Specialized, Refined, Characteristic and Novel Small and Medium-Size Enterprise to MicroPort® EP, MicroPort® Endovascular and MicroPort® NeuroTech in recognition of MicroPort® and the subsidiary companies’ innovative achievements in the past years. In the future, the MicroPort® companies will continue to take the specialized, refined, characteristic and novel approaches to adhere to independent innovation, enhance core competitiveness, explore domestic and overseas markets, and establish competitive and influential products and brands, so as to build more leading enterprises in various segments of the medical device industry.